The Predictive Significance of Various Prognostic Scoring Systems on the Efficacy of Immunotherapy in Non‐Small Cell Lung Cancer Patients: A Retrospective Study

• Published in: Health science reports Vol. 8; no. 4; pp. e70713 - n/a
• Main Authors: Liu, Jianying, Chen, Jinzhan, Xie, Congyi, Chen, Haiyan, Yang, Shuwen, Jiang, Hongni, Xu, Yijiao
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.04.2025; John Wiley and Sons Inc; Wiley
• Subjects: Cancer therapies; Cell death; Chemotherapy; Combination therapy; Gender; Gustave Roussy Immune Score; immune checkpoint inhibitors; Immunotherapy; Lung cancer; Lung Immune Prognostic Index; Medical prognosis; modified Glasgow Prognostic Score; non‐small cell lung cancer; Original Research; prognostic analysis; Proteins; Radiation therapy; Lung Immune Prognostic Index; immune checkpoint inhibitors; modified Glasgow Prognostic Score; non‐small cell lung cancer; prognostic analysis; Gustave Roussy Immune Score
• ISSN: 2398-8835; 2398-8835
• DOI: 10.1002/hsr2.70713

ABSTRACT Background and Aims To evaluate the efficacy and prognostic value of various immunoprognostic scoring systems—Lung Immune Prognostic Index (LIPI), modified Glasgow Prognostic Score (mGPS), and Gustave Roussy Immune Score (GRIm)—in non‐small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Methods We conducted a retrospective analysis of clinical data from 219 NSCLC patients treated with ICIs at Zhongshan Hospital (Xiamen), Fudan University from June 1, 2019 to January 31, 2024. The therapeutic efficacy and predictive capabilities of the scoring systems were assessed using Kaplan–Meier curves, Cox proportional hazards models, time‐dependent ROC curves, and random survival forest models. Results The median follow‐up was 29 months (IQR: 25.96–32.04), resulting in 93 observed deaths. Both LIPI and GRIm scores correlated with declining overall survival (OS) and progression‐free survival (PFS) as risk levels increased. LIPI demonstrated superior predictive performance at 12, 24, and 36 months (AUC: 0.70, 0.62, 0.61, respectively). Multivariate analysis identified immune‐related adverse events (irAEs) and lactate dehydrogenase (LDH) levels as independent prognostic factors for OS. Conclusion LIPI serves as an effective prognostic tool for NSCLC patients receiving immunotherapy, outperforming individual inflammatory markers. Additionally, irAEs and LDH levels are significant independent prognostic factors for OS.